ライフサイエンスコーパス: seroprevalence

1 0.65 to 0.81]) as associated with H. pylori seroprevalence.

2 imilar results were observed for hotspots of seroprevalence.

3 the humoral immune response and to determine seroprevalence.

4 ce the observed relationship between age and seroprevalence.

5 ulate a pooled estimate of hepatitis D virus seroprevalence.

6 sociated herpesvirus (KSHV) has a restricted seroprevalence.

7 t, controlling for income per person and HIV seroprevalence.

8 r cCMV in countries with low to intermediate seroprevalence.

9 esults in a high post-vaccination poliovirus seroprevalence.

10 We previously reported an unexpectedly high seroprevalence (~10%) of N-methyl-D-aspartate-receptor s

11 S) 1988-1994 dataset found a relatively high seroprevalence (21%) of hepatitis E virus (HEV) infectio

12 ryzomys longicaudatus displaying the highest seroprevalence (5.9%), followed by Abrothrix longipilis

13 vs 0.7/1,000,000 person-years [p<0.01]) and seroprevalence (7.9 vs 3.3/100,000[p=0.04]) were also hi

14 ed an association between TLR1 and H. pylori seroprevalence, a finding that requires replication in n

15 es C Ad6 and Ad26 are being pursued as lower-seroprevalence Ad vectors but differ at the DNA level by

16 gene for IIIa capsid cement protein of lower-seroprevalence adenovirus serotype 6.

17 ation seroconverted due to infection and the seroprevalence after the wave rose to 23%, either due to

18 Seroprevalence afterwards was 23.0% (95% CI 17.7, 29.3)

19 Faso, the general population has an antibody seroprevalence against 12 pneumococcal serotypes similar

20 This study shows high seroprevalence against group A meningococci in Burkina F

21 Supplemental mOPV1 resulted in almost total seroprevalence against poliovirus type 1, which is consi

22 ucted a study in Moradabad in 2007 to assess seroprevalence against poliovirus types 1, 2, and 3 in c

23 cent absence of poliomyelitis cases; whereas seroprevalence against types 2 and 3 was expected for ro

24 Survey (NHANES), we examined HSV-1 and HSV-2 seroprevalence among 14- to 49-year-olds in the United S

25 s detected in poultry, and consequently, the seroprevalence among exposed humans was between 5.6% and

26 Lower seroprevalence among groups suggest that they represent

27 The baseline seroprevalence among infants aged 6-9 months in 2014 was

28 The overall seroprevalence among the sH3N2-primed population against

29 nt associations were found between T. gondii seroprevalence and a history of major depression (n = 57

30 a significant relationship between T. gondii seroprevalence and bipolar disorder type I for responden

31 a showed a striking relationship between age seroprevalence and clinical data, demonstrating the proo

32 The association between H. pylori seroprevalence and colorectal cancer risk was estimated

33 There was no association between baseline seroprevalence and detection of precancer during follow-

34 as demonstrated by the presence of increased seroprevalence and elevated viral loads, but the mechani

35 To understand prior mumps seroprevalence and factors associated with the presence

36 non-inferiority margin of 10% for poliovirus seroprevalence and measles, rubella, and yellow fever se

37 vitro, hindering efforts to understand their seroprevalence and pathogenicity.

38 on in children and adults to determine HHV-8 seroprevalence and potential routes of transmission.

39 The seroprevalence and risk factors identified in this study

40 Seroprevalence and seroprotection were defined as an HI

41 We also investigated the seroprevalence and specificity of GII.4 antibody in the

42 Seroprevalence and vaccination coverage data indicate hi

43 stic pathologies mirror the geographic HHV-8 seroprevalence, and certain groups of patients are at hi

44 The factors driving the decline in H. pylori seroprevalence appear to be acting preferentially on the

45 gher in donors living in a high anti-HEV IgG seroprevalence area (1.9% versus 0.7%, P < 0.001) and in

46 Analysis indicated bird and flock seroprevalence as 4.2% (11/262) and 23.1% (9/39), respec

47 We assessed cytomegalovirus seroprevalence as a risk factor for morbidity and mortal

48 udies are limited by lack of aquaporin-4-IgG seroprevalence assessment, absence of population-based U

49 In the seroprevalence assessment, PV type 1 and 3 seroprevalenc

50 Despite substantial reductions in seroprevalence, at least 9% of males were seropositive f

51 Seroprevalence before the pandemic was 6.7% (95% CI 5.0,

52 patients were anti-HEV IgG positive with the seroprevalence being highest in those from the Midwest (

53 HHV-8 seroprevalence by either assay was 75.4% (95% confidence

54 Familial dependence in HHV-8 seroprevalence by either assay was found between mother-

55 Reported seroprevalence by MN ranged from 0.6% to 9% (median, 2.7

56 here was a significant difference in overall seroprevalence by region: 26.2% in LRR and 17.1% in URR

57 Seroprevalence conferred protection against subsequent H

58 rticles were pooled to estimate age-specific seroprevalence curves in 1990 and 2005, and to produce a

59 sic results from epidemiological theory with seroprevalence data and highly spatially resolved data a

60 Human papillomavirus (HPV) seroprevalence data can help define the epidemiology of

61 Our study also highlights the importance of seroprevalence data for precise quantitative analysis of

62 uito representations, using surveillance and seroprevalence data for several ZIKV outbreaks in Pacifi

63 ata collected over 14 years and longitudinal seroprevalence data from 2010 to 2013.

64 ystematic review, antibody to HCV (anti-HCV) seroprevalence data from 232 articles were pooled to est

65 eak potential, demonstrated using 2006 mumps seroprevalence data from Belgium and Belgian vaccination

66 els, but which is a prominent feature of the seroprevalence data from Paraguay.

67 Seroprevalence data reported by the studies ranged from

68 The age-specific HPV seroprevalence data were best explained by a partner acq

69 In this age group, HSV-1 seroprevalence declined >29% from 1976-1980 to 2005-2010

70 ong adolescents aged 14-19 years, among whom seroprevalence declined by nearly 23%, from 39.0% to 30.

71 From 1999-2004 to 2005-2010, HSV-1 seroprevalence declined by nearly 7% (P < .01), but HSV-

72 tic models using information on age-specific seroprevalence demonstrated a decrease in the transmissi

73 e declined by nearly 7% (P < .01), but HSV-2 seroprevalence did not change significantly.

74 Pandemic H1N1 seroprevalence did not vary in relation to ambient tempe

75 % (median, 2.7%), which was greater than the seroprevalence estimated through the WHO-recommended cas

76 ich was not significantly different from the seroprevalence estimated through the WHO-recommended cas

77 and/or in metropolitan areas had the highest seroprevalence estimates.

78 Remarkably, canine seroprevalence for different HuNoV genotypes mirrored th

79 ity (P = .003) were associated with a higher seroprevalence for genus beta HPV types.

80 Baseline seroprevalence for HPV16 L1 was associated with decrease

81 The incidence of PML is very low, whereas seroprevalence for the virus is high, suggesting infecti

82 Human seroprevalence for Toxocara antibodies varies with facto

83 Seroprevalence for type 1 wild poliovirus was >96.4% for

84 Between settings, seroprevalences for merozoite antigens were similar betw

85 We also reviewed HSV-1 and HSV-2 seroprevalence from 1976-1980 to 2005-2010.

86 The largest decline in HSV-1 seroprevalence from 1999-2004 to 2005-2010 was observed

87 The pooled HCV seroprevalence from all cohorts was 2.98% (95% CI 2.86-3

88 ulation, there was a significant increase in seroprevalence, from 26% (n = 56/215 dogs) on the day of

89 where the epidemic started earlier and adult seroprevalence has been higher, HIV adaptation to HLA in

90 a booster at age 10-14 years decreased HBsAg seroprevalence if participants were born to HBsAg-positi

91 We estimated seroprevalence in 1999-2004 and 2005-2010, stratified by

92 We set out to examine age-related seroprevalence in a community where we have previously c

93 ak sample, and near-farm by immunoglobulin M seroprevalence in a municipal population sample.

94 cted infections, was estimated regionwide by seroprevalence in a pre- versus postoutbreak sample, and

95 Although HEV seroprevalence in Afghanistan is not known, HEV infectio

96 on was found to significantly decrease HBsAg seroprevalence in childhood through young adulthood and

97 1, 2014, for studies containing data for HCV seroprevalence in different population groups in WHO-def

98 ed efficacy of catch-up vaccination on HBsAg seroprevalence in early adulthood was 21% (95% CI 10%-30

99 s have increased in cattle along with rising seroprevalence in elk.

100 Seroprevalence in humans was examined by screening sera

101 egate genetically from Ad5 and exhibit lower seroprevalence in humans, making them attractive vaccine

102 In 2012-2013, we conducted a survey of HPV seroprevalence in males to assess whether or not a herd

103 The findings suggest that lower HPV seroprevalence in older US women primarily reflects coho

104 The expected HCV seroprevalence in Philadelphia during 2010-2013 was calc

105 The role of putatively protective antibody seroprevalence in preventing pneumococcal meningitis in

106 Furthermore, seroprevalence in swine sera from 2006 to 2008 suggested

107 L and there was a significantly higher HBsAg seroprevalence in the HIV cohort, compared to the contro

108 e for different HuNoV genotypes mirrored the seroprevalence in the human population.

109 rsenic was inversely associated with VZV IgG seroprevalence in the U.S.

110 nfluenza by investigating the prevalence and seroprevalence in this potentially vulnerable population

111 00000 with a prevalence of HSV-2 of 16% (the seroprevalence in US adults with unknown symptom status)

112 nclude species and populations with high AIV seroprevalences, in addition to those with high infectio

113 in the Ugandan population-based sample, KSHV seroprevalence increased from 10% among 2-year-old child

114 HHV-8 seroprevalence increased from 16% among children aged 1.

115 In the Ugandan clinic-based sample, seroprevalence increased from 9.3% among 2-year-old chil

116 Seroprevalence increases with age, but it is not clear i

117 Worldwide, seroprevalence is <10% up to 10 years of age, with the e

118 tion is similarly high in males and females, seroprevalence is lower in males.

119 Cytomegalovirus seroprevalence is not associated with prolonged mechanic

120 In a population-based sample, T. gondii seroprevalence is not elevated in unipolar mood disorder

121 n rates but lack precision in settings where seroprevalence is still high.

122 f transmission settings, as characterised by seroprevalence levels among 9-y-olds (SP9).

123 Helicobacter pylori seroprevalence levels in US adults participating in the

124 Although seroprevalence levels remained similar to those found in

125 Despite relatively high PV seroprevalence, Namibia might remain at risk for a PV ou

126 herefore not always responsible for the high seroprevalence observed in adults.

127 The seroprevalence of 1 cutaneous HPV type was 96% and 90% f

128 Using multiplex serology, we determined the seroprevalence of 10 human PyVs (BK, JC, KI, WU, MCV, HP

129 M+; 4.4% were F+M-, resulting in the overall seroprevalence of 11.4%.

130 We found an overall IgG seroprevalence of 22.4% (8%-86.4%) depending on the geog

131 For testing a population with an HCVAb seroprevalence of 3.25%, all strategies when adopting qu

132 s 17.8%), while Mexican Americans had higher seroprevalence of 31/33/45/52/58 (23.6% vs 15.9%) (P < .

133 panic whites, non-Hispanic blacks had higher seroprevalence of 31/33/45/52/58 (36.8% vs 15.9%) and 16

134 for HCV (42 648 individuals), with a pooled seroprevalence of 5.73% (95% CI 4.90-6.56).

135 public of Ireland, with an overall estimated seroprevalence of 50% (n = 314/625 dogs).

136 ical patients with a pretransfusion B19V IgG seroprevalence of 78%.

137 The seroprevalence of AiV is approximately 60% in children u

138 Seroprevalence of all screened AB was comparable in heal

139 Seroprevalence of all type categories, especially HPV 31

140 At baseline, the seroprevalence of anti-A(H5N1) antibodies (titer, >/=80)

141 However, we observed increasing seroprevalence of anti-HBc and isolated anti-HBs when su

142 ence, there is a significant increase in the seroprevalence of anti-HBs, anti-HBc, and HBV DNA, indic

143 We estimated the seroprevalence of anti-HEV antibody and annual incidence

144 The low and similar seroprevalence of anti-HEV between the at-risk group and

145 Non-Hispanic blacks had the lowest seroprevalence of anti-HEV immunoglobulin G (15.3%, 95%

146 We show that the seroprevalence of anti-M2 antibodies increased with age

147 We then assessed the seroprevalence of antibodies to Ebola virus in a cross-s

148 The seroprevalence of antibodies to HEV in US service member

149 objectives of this survey were to assess the seroprevalence of antibodies to poliovirus types 1 and 3

150 s were factors independently associated with seroprevalence of any HPV vaccine type among both female

151 .5% among females and 12.2% among males; the seroprevalence of any HPV vaccine type increased with ag

152 Non-Hispanic blacks had a higher seroprevalence of any HPV vaccine type than that observe

153 The seroprevalence of B burgdorferi among patients with uvei

154 The seroprevalence of B burgdorferi among uveitis patients w

155 Eligible studies had to report seroprevalence of both hepatitis B surface antigen (HBsA

156 We found that seroprevalence of Brucella spp. and T. gondii antibodies

157 the need for a greater understanding of the seroprevalence of chlamydial infection in US populations

158 The seroprevalence of CMV among the 462 enrolled mothers was

159 The seroprevalence of E. histolytica was 33% (14/43) from th

160 Seroprevalence of EBV, CMV, herpes simplex virus types 1

161 The overall seroprevalence of HBsAg and anti-HBc was significantly l

162 We recorded a high seroprevalence of HCV across populations of sub-Saharan

163 The pooled seroprevalence of HCV was 11.87% (95% CI 7.05-16.70) acr

164 vaccinations, of their effectiveness, and of seroprevalence of hepatitis A antibody and anti-HB surfa

165 ive antiviral therapy, the estimated overall seroprevalence of hepatitis B surface antigen remains hi

166 In west Africa, the pooled seroprevalence of hepatitis D virus was 7.33% (95% CI 3.

167 tial modes of transmission and determine the seroprevalence of HEV among animal handlers at the insti

168 The seroprevalence of HEV in the civilian noninstitutionaliz

169 The weighted national seroprevalence of HEV in the U.S. is much less than prev

170 for HEV was used, we estimated the weighted seroprevalence of HEV infection among U.S. individuals 6

171 Based on these results, the seroprevalence of HEV is only one-third as high as previ

172 Nevertheless, the reported seroprevalence of HEV varies greatly depending on the ge

173 The weighted national seroprevalence of HEV was 6% (95% confidence interval [C

174 obtained with a high performance assay, the seroprevalence of HEV was estimated at 6.0% in the U.S.

175 We determined seroprevalence of HPV 6/11/16/18/31/33/45/52/58 among 49

176 We determined the seroprevalence of HPV types 6, 11, 16, and 18 (HPV types

177 In 2005-2010, the seroprevalence of HSV-1 was 53.9%, and the seroprevalenc

178 e seroprevalence of HSV-1 was 53.9%, and the seroprevalence of HSV-2 was 15.7%.

179 ssion during coitus and contributing to high seroprevalence of HSV-2 worldwide.

180 e in good agreement with the near-ubiquitous seroprevalence of IDV previously found.

181 The overall age-adjusted seroprevalence of IgG antibody to mumps virus during 199

182 In spite of the high seroprevalence of infection, the risk factors that predi

183 ission is primarily responsible for the high seroprevalence of KSHV among adults that is observed thr

184 Compared with the general population, seroprevalence of MERS-CoV antibodies was significantly

185 Seroprevalence of MERS-CoV antibodies was significantly

186 We evaluated the seroprevalence of myelin oligodendrocyte glycoprotein im

187 practices were inversely associated with the seroprevalence of polyomaviruses and herpesviruses.

188 Seroprevalence of polyomaviruses ranged from 38.5% to 99

189 owever, limited data exist on the population seroprevalence of PyVs and individual characteristics th

190 Age-specific seroprevalence of reference strain SBA titres most likel

191 on to ambient temperature changes, while the seroprevalence of seasonal H3N2 and H1N1 influenza virus

192 c enzyme immunoassay was used to measure the seroprevalence of serum immunoglobulin G (IgG) antibody

193 t schizophrenia is associated with increased seroprevalence of T. gondii, but a possible link of the

194 from A. baumannii, was used to determine the seroprevalence of the K1 capsule in a collection of 100

195 The seroprevalence of these novel rhesus monkey adenovirus v

196 usion, the results of this study showed high seroprevalence of toxocariasis among clinically suspecte

197 is, malnutrition was associated with a lower seroprevalence of type 3 antibodies.

198 ated the association between arsenic and the seroprevalence of VZV IgG antibody in a representative s

199 The seroprevalence of wild poliovirus types 2 and 3 increase

200 The seroprevalence of ZIKV was 6.2% based on ZIKV immunoglob

201 Hepatitis E virus (HEV) seroprevalences of 0.3%-53% were reported from industria

202 The seroprevalences of antibodies to AAV7 and to AAV8 were l

203 Seroprevalences of antibodies to poliovirus types 1, 2,

204 Among subjects with 0 tOPV doses, the seroprevalences of antibodies to type 3 were 50%, 77%, a

205 Although the seroprevalences of both viruses were low in Finland, our

206 The seroprevalences of HPV types 6, 11, 16, and 18 among fem

207 The seroprevalences of pandemic H1N1, seasonal H1N1, and H3N

208 rs to be lower than in populations with high seroprevalence, older epidemics, and/or limited HLA dive

209 In a second patient cohort of mixed HIV seroprevalence, plasma PIIINP concentration was increase

210 ub-Saharan Africa and other high HIV and CMV seroprevalence populations globally.

211 isk for a PV outbreak, particularly in lower-seroprevalence populations, such as HIV-positive females

212 Seroprevalence pre-alloHSCT was 13%.

213 emonstrating the proof-of-principle that age seroprevalence predicts transmission rates and therefore

214 We examined seroprevalence (presence of detectable antibodies in ser

215 Annual brucellosis seroprevalence ranged from 8.7% (95% CI = 1.8-15.6) to 4

216 s were seropositive for at least 1 PyV, with seroprevalences ranging from 17.6% (HPyV9) to 99.1% (HPy

217 ectional study of 152 U.K. adults, with HCMV seroprevalence rate of 36%, we find that HCMV seropositi

218 antenatal human immunodeficiency virus (HIV) seroprevalence rates ( approximately 30%) with low perin

219 d individuals are needed to establish global seroprevalence rates and potential disease associations.

220 Seroprevalence rates and titers of neutralizing antibodi

221 The primary outcomes were seroprevalence rates for poliovirus 4-6 weeks post-vacci

222 med a systematic review for reports of HBsAg seroprevalence rates in 102 countries (covering PubMed f

223 All seroprevalence rates in excess of 60% were found in mari

224 The decline of seroprevalence recently observed in many countries might

225 Hepatitis C virus (HCV) seroprevalence remains high in people who inject drug (P

226 Seroprevalence rose throughout childhood, from 8% in chi

227 /NMOSD and aquaporin-4-IgG seroincidence and seroprevalence (sera collected in 80-84% of IDD) among p

228 impact of congenital CMV infections in high-seroprevalence settings.

229 Seroprevalence should be considered in deciphering patte

230 Wang et al. overinterpret the results of seroprevalence studies and take too little account of un

231 Poliovirus (PV) antibody seroprevalence studies assess population immunity, verif

232 Representative, population-based seroprevalence studies complement clinical trials and pr

233 t and past ZIKV infections for surveillance, seroprevalence studies, and intervention trials.

234 ections, hence, facilitating epidemiological seroprevalence studies.

235 meningitis belt, we conducted a pneumococcal seroprevalence study during a meningococcal meningitis e

236 This seroprevalence study provided extremely useful informati

237 This was a cross-sectional seroprevalence study using de-identified blood samples a

238 An 8-week seroprevalence study was conducted in an urban ED in 201

239 We conducted a seroprevalence survey among students to assess vaccinati

240 conducted a household-based, age-stratified seroprevalence survey in Bamako, Mali, in 2012, 2 years

241 ng 2011-2014, Nigeria conducted serial polio seroprevalence surveys (SPS) in Kano Metropolitan Area,

242 conducted routine immunization coverage and seroprevalence surveys before and after a September 2007

243 The results from the polio seroprevalence surveys conducted in Kano Metropolitan Ar

244 tive influenza surveillance and intermittent seroprevalence surveys in a household-based cohort in Vi

245 We identified 256 seroprevalence surveys in emigrants from 52 countries (i

246 la Mohammed Specialist Hospital (Kano) for 3 seroprevalence surveys.

247 HIV-positive females had significantly lower seroprevalence than HIV-negative females for PV1 (91.8%

248 We calculated overall seroprevalence through a random effects meta-analysis mo

249 E HSV-1 is an important pathogen with a high seroprevalence throughout the human population.

250 ns than in the general U.S. population, with seroprevalence to H. pylori approaching 75%.

251 y of reported cases, molecular epidemiology, seroprevalence, vaccine coverage, and adequacy of survei

252 The 2011 study showed seroprevalence values of 81%, 75%, and 73% for polioviru

253 Among children aged 36-47 months, seroprevalence values were greater (91%, 87%, and 85% fo

254 Seroprevalence varied among species (highest in eiders (

255 cLIA seroprevalence varied with previous exposure; the preval

256 Because of its very low human seroprevalence, vesicular stomatitis virus (VSV) has pro

257 Most humans are immune to Ad5, so lower-seroprevalence viruses like human Ad6 and Ad26 are being

258 In east and southern Africa, seroprevalence was 0.05% (0.00-1.78) in general populati

259 Overall IgM seroprevalence was 1% (0%-4.6%).

260 Rodent seroprevalence was 1.4%, with Oligoryzomys longicaudatus

261 HIV-1 seroprevalence was 11% (74/655) in children under 15 yea

262 The pooled HCV seroprevalence was 2.65% (95% CI 2.53-2.78) across all 1

263 HHV-8 seroprevalence was 2.8% (29/1023) among blood donors, 7.

264 In central Africa, seroprevalence was 25.64% (12.09-42.00) in general popul

265 = 1.00 (95% CI = 0.85-1.16) when brucellosis seroprevalence was 30%.

266 For any HPV vaccine type, the seroprevalence was 32.5% among females and 12.2% among m

267 Human herpesvirus 8 seroprevalence was 4% (10/249) in donors and 18% (93/517

268 In children 1-9 years old, seroprevalence was 4.4% in LRR and 3.9% in URR.

269 With KIR3DS1 plus HLA-B Bw4-80I, the KSHV seroprevalence was 40% lower (adjusted OR for the combin

270 Similarly, the KSHV seroprevalence was 40% lower (adjusted OR, 0.6; P = .01)

271 Among females, seroprevalence was 40.5% for any of the 9 vaccine types,

272 Maternal seroprevalence was 61%, birth prevalence was 0.37%, resu

273 The overall seroprevalence was 64.0% for AMA-1, 39.5% for MSP-119, a

274 KSHV seroprevalence was 7.5%-9.0% among South African childre

275 HPV 6, 11, 16, and 18 seroprevalence was 8.1%, 13.9%, 12.7%, and 10.8%, respec

276 The seroprevalence was 94.6% for PV1, 97.0% for PV2, and 85.

277 Seroprevalence was also not associated with poor outcome

278 Seroprevalence was compared to the age-specific NmA meni

279 ses regarding anti-HEV and anti-Yersinia IgG seroprevalence was conducted.

280 Seroprevalence was higher among US-born non-Hispanic bla

281 Overall, H. pylori seroprevalence was higher in cases (46.1%) than in contr

282 Seroprevalence was highest for HPV types 4 (46%), 1 (37%

283 e seroprevalence assessment, PV type 1 and 3 seroprevalence was lower among women aged 15-29 years in

284 cLIA seroprevalence was lower than VLP ELISA, suggesting that

285 Seroprevalence was much higher than AIV infection based

286 adjustment for confounding, cytomegalovirus seroprevalence was not associated with the primary outco

287 2013 H3N2v viruses was >50%, and age-related seroprevalence was observed.

288 associations were identified (p</=0.05), AI seroprevalence was positively associated with exposure t

289 HIV seroprevalence was remarkably high, ranging from 11%-26%

290 The HPgV-2 seroprevalence was significantly higher (P < 0.0001) amo

291 Seroprevalence was significantly higher to 2013 H3N2v th

292 Seroprevalence was significantly lower in the 1967-1976

293 tively).In 2013, the results showed that the seroprevalence was unexpectedly low among infants aged 6

294 Poliovirus seroprevalence was universally high (>97%) after vaccina

295 ional surveys on HBV surface antigen (HBsAg) seroprevalence were conducted in 1996-2000 and 2008-2012

296 Poliovirus type 1, 2, and 3 seroprevalences were 88% (95% confidence interval [CI],

297 Among males, the seroprevalences were lower for each type, with 6.3% obse

298 uthors assessed the association of H. pylori seroprevalence with risk of colorectal cancer in a large

299 g persistence of the virus results in a high seroprevalence worldwide and may contribute to age-relat

300 Data on residual infant deaths and maternal seroprevalence would be valuable inputs into considerati